EA201792495A1 - Способ оптимизации предварительного установления временной зависимости концентрации контрастного агента при диагностической визуализации с использованием магнитно-резонансной системы - Google Patents

Способ оптимизации предварительного установления временной зависимости концентрации контрастного агента при диагностической визуализации с использованием магнитно-резонансной системы

Info

Publication number
EA201792495A1
EA201792495A1 EA201792495A EA201792495A EA201792495A1 EA 201792495 A1 EA201792495 A1 EA 201792495A1 EA 201792495 A EA201792495 A EA 201792495A EA 201792495 A EA201792495 A EA 201792495A EA 201792495 A1 EA201792495 A1 EA 201792495A1
Authority
EA
Eurasian Patent Office
Prior art keywords
contrast agent
concentration
magnetic
patient
optimization
Prior art date
Application number
EA201792495A
Other languages
English (en)
Other versions
EA037889B1 (ru
Inventor
Мартин Рорер
Грегор Йост
Хубертус Пич
Клаус-Петер Райзингер
Харальд Крамер
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201792495A1 publication Critical patent/EA201792495A1/ru
Publication of EA037889B1 publication Critical patent/EA037889B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/0263—Measuring blood flow using NMR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
    • G01R33/56308—Characterization of motion or flow; Dynamic imaging
    • G01R33/56316—Characterization of motion or flow; Dynamic imaging involving phase contrast techniques
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
    • G01R33/5635—Angiography, e.g. contrast-enhanced angiography [CE-MRA] or time-of-flight angiography [TOF-MRA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Signal Processing (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Способ предварительного установления временной зависимости концентрации контрастного агента на местоположении в кровеносном сосуде пациента в контексте усиленной контрастным агентом магнитно-резонансной (MR) визуализации области интереса только во время начальной фазы заполнения контрастным агентом расположенного в области интереса кровеносного сосуда. Способ включает в себя обнаружение ожидаемого расширения профиля B(t) болюса контрастного агента согласно равенству ΔW = W2 - W1, где W1 является первой шириной профиля болюса контрастного агента на предварительно установленном первом местоположении сосуда пациента, а W2 является второй шириной профиля концентрации контрастного агента на предварительно установленном втором местоположении сосуда, расположенном в области интереса пациента. Расширение обнаруживают путем установления по меньшей мере одного параметра потока, который зависит по меньшей мере от одного свойства тока крови пациента на его третьем местоположении сосуда и который коррелирует с ожидаемым расширением профиля болюса контрастного агента.
EA201792495A 2015-05-13 2016-05-10 Способ прогнозирования временной зависимости концентрации контрастного агента при диагностической визуализации с использованием магнитно-резонансной системы EA037889B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15167568.3A EP3093678A1 (de) 2015-05-13 2015-05-13 Verfahren zur optimierung der vorbestimmung des zeitlichen verlaufes einer kontrastmittelkonzentration bei der diagnostischen bildgebung mit einem magnetresonanzsystem
PCT/EP2016/060371 WO2016180799A1 (en) 2015-05-13 2016-05-10 Method for optimizing the predetermination of the time profile of a contrast agent concentration in diagnostic imaging using a magnetic resonance system

Publications (2)

Publication Number Publication Date
EA201792495A1 true EA201792495A1 (ru) 2018-05-31
EA037889B1 EA037889B1 (ru) 2021-06-01

Family

ID=53175349

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792495A EA037889B1 (ru) 2015-05-13 2016-05-10 Способ прогнозирования временной зависимости концентрации контрастного агента при диагностической визуализации с использованием магнитно-резонансной системы

Country Status (19)

Country Link
US (1) US10852378B2 (ru)
EP (2) EP3093678A1 (ru)
JP (1) JP6763882B2 (ru)
KR (1) KR102538423B1 (ru)
CN (1) CN108283017B (ru)
AU (1) AU2016259747B2 (ru)
BR (1) BR112017026282A8 (ru)
CA (1) CA2985688C (ru)
CL (1) CL2017002873A1 (ru)
EA (1) EA037889B1 (ru)
ES (1) ES2726073T3 (ru)
HK (1) HK1255646A1 (ru)
IL (1) IL255432B (ru)
MX (1) MX2017014517A (ru)
PH (1) PH12017502068A1 (ru)
PL (1) PL3295197T3 (ru)
TN (1) TN2017000481A1 (ru)
TR (1) TR201905880T4 (ru)
WO (1) WO2016180799A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3203255A1 (de) * 2016-02-02 2017-08-09 Bayer Pharma Aktiengesellschaft Bestimmung der mindestdauer eines kontrastmittelbolus und limitierung von injektionsraten
EP3413073A1 (de) * 2017-06-07 2018-12-12 Siemens Healthcare GmbH Kontrastmittelunterstützte mr-angiographie mit ermittlung der flussgeschwindigkeit des kontrastmittels
CN111544019B (zh) * 2020-04-10 2023-07-14 北京东软医疗设备有限公司 确定造影剂注入时间的方法、装置及系统

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5590654A (en) * 1993-06-07 1997-01-07 Prince; Martin R. Method and apparatus for magnetic resonance imaging of arteries using a magnetic resonance contrast agent
US5583902A (en) * 1995-10-06 1996-12-10 Bhb General Partnership Method of and apparatus for predicting computed tomography contrast enhancement
US6425864B1 (en) * 1999-04-15 2002-07-30 General Electric Company Method and apparatus for optimal imaging of the peripheral vasculature
US6597937B2 (en) * 2001-02-05 2003-07-22 Koninklijke Philips Electronics N.V. Self-adaptive tracking and phase encoding during data collection for contrast-enhanced MRA and dynamic agent uptake studies
US6597938B2 (en) * 2001-08-16 2003-07-22 Koninklijke Philips Electronics, N.V. System for assistance of parameter determination and diagnosis in MRI dynamic uptake studies
DE102005006657A1 (de) 2005-02-14 2006-08-31 Siemens Ag Verfahren zur Vorhersage des Kontrastmittelflusses in einem lebenden Körper
US8208699B2 (en) * 2005-10-05 2012-06-26 Koninklijke Philips Electronics N.V. Method and apparatus for predicting enhancement in angiography
US8315449B2 (en) 2008-06-24 2012-11-20 Medrad, Inc. Identification of regions of interest and extraction of time value curves in imaging procedures
CN103126673B (zh) 2011-11-25 2016-08-03 东芝医疗系统株式会社 一种用于确定ce-mra扫描的触发时机的装置和方法
US9014781B2 (en) 2012-04-19 2015-04-21 General Electric Company Systems and methods for magnetic resonance angiography
DE102013201136B4 (de) 2013-01-24 2023-01-19 Siemens Healthcare Gmbh Vorhersage eines voraussichtlichen Kontrastmittelverlaufs
DE102013204994B4 (de) 2013-03-21 2019-05-29 Siemens Healthcare Gmbh Zeitaufgelöste Phasenkontrast-MR-Bildgebung mit Geschwindigkeitskodierung
US11141535B2 (en) 2017-08-31 2021-10-12 Bayer Healthcare Llc Fluid path impedance assessment for improving fluid delivery performance

Also Published As

Publication number Publication date
CA2985688C (en) 2023-07-25
MX2017014517A (es) 2018-03-15
WO2016180799A1 (en) 2016-11-17
EP3295197B1 (en) 2019-03-20
EA037889B1 (ru) 2021-06-01
US10852378B2 (en) 2020-12-01
HK1255646A1 (zh) 2019-08-23
KR102538423B1 (ko) 2023-06-01
JP2018514337A (ja) 2018-06-07
EP3093678A1 (de) 2016-11-16
AU2016259747B2 (en) 2021-10-28
CN108283017A (zh) 2018-07-13
BR112017026282A8 (pt) 2023-04-18
JP6763882B2 (ja) 2020-09-30
CL2017002873A1 (es) 2018-06-01
PH12017502068A1 (en) 2018-04-23
ES2726073T3 (es) 2019-10-01
AU2016259747A1 (en) 2017-11-30
IL255432B (en) 2021-10-31
CA2985688A1 (en) 2016-11-17
TN2017000481A1 (en) 2019-04-12
BR112017026282A2 (pt) 2023-02-07
US20180284207A1 (en) 2018-10-04
TR201905880T4 (tr) 2019-05-21
KR20180006410A (ko) 2018-01-17
EP3295197A1 (en) 2018-03-21
IL255432A0 (en) 2017-12-31
PL3295197T3 (pl) 2019-08-30
CN108283017B (zh) 2021-01-12

Similar Documents

Publication Publication Date Title
EA201792495A1 (ru) Способ оптимизации предварительного установления временной зависимости концентрации контрастного агента при диагностической визуализации с использованием магнитно-резонансной системы
TR201907559T4 (tr) Bir devridaim pompa sisteminin ayarlanmasına yönelik yöntem.
TW201408262A (en) Method of extracting arterial input function and its application for dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
EA201291040A1 (ru) Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином
JP2018513715A5 (ru)
WO2017040523A1 (en) Leakage correction for dsc-perfusion mri by accounting for bidirectional contrast agent exchange
RU2013155644A (ru) Способ диагностики стадий хронической болезни почек
RU2013155841A (ru) Способ ранней диагностики хронической болезни почек
WO2017144239A3 (en) Determination of the minimum duration of a contrast agent bolus and limitation of injection rates
Kuwabara Axonal Guillain–Barré syndrome is underestimated in Europe?
SG11202107228YA (en) Intravenous therapy system for blood vessel detection
EA201592016A1 (ru) Блок управления, способ определения давления в кровеносном сосуде, в частности в артериовенозной фистуле, и устройство для экстракорпоральной обработки крови
Kawaguchi et al. Cost-effectiveness analysis of celecoxib in the treatment of patients with chronic pain in Japan
KR20150045659A (ko) 혈관 신호강도-직경 비 유도 시스템 및 방법
Wang et al. The comparison of diffusion and perfusion characteristics among the different types of uterine fibroids based on T2WIs: and intravoxel incoherent motion MRI study
고인옥 et al. Effect of Gd-based MR contrast agents on CT attenuation of PET/CT for quantitative PET-MRI study
Park et al. Intrahepatic hemorrhage in a patient with antiphospholipid antibody syndrome
Myung et al. A case of cerebral and splenic infarctions after Histocaryl injection in esophageal varix bleeding
Roayaie et al. How Is BCLC Stage C HCC Treated In Real-Word Practice And What Outcomes Are Obtained?: 1403
阿部香代子 Assessment of cerebrospinal fluid flow patterns using the time-spatial labeling inversion pulse technique with 3T MRI: Early clinical experiences.
Joo et al. Monitoring therapeutic effect of a vascular disrupting agent: correlation between perfusion parameters derived from intravoxel incoherent motion diffusion-weighted imaging and dynamic contrast enhanced MRI
Dolui et al. Comparison of PASL, pCASL and background suppressed 3D pCASL in a Clinical Population
Nguyen et al. Measurement of blood-brain barrier permeability in acute ischaemic stroke using first-pass perfusion CT
Kida Limbic leukoencephalopathy: case report
Federspiel et al. Selective ASL delineates borderzone territories in patients with stenosis of the middle cerebral artery